Akèy › Maladi Crohn › Arizona
Etid klinik pou Maladi Crohn nan Arizona
17 etid pou Maladi Crohn ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- GI Alliance - Sun City ( Site 5118), Sun City
- University of Arizona Clinical and Translational Sciences Research Center ( Site 5111), Tucson
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Elite Clinical Studies /ID# 280477, Phoenix
- Gi Alliance - Arizona Digestive Health - Sun City /ID# 284084, Sun City
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- AZ Gastro Care, Chandler
- Spectrum Research Institute LLC, Gilbert
- GI Alliance- Sun City, Sun City
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- AZ Gastro Care, Chandler
- Research Solutions of Arizona, Litchfield Park
- Mayo Clinic, Scottsdale
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Onyx Clinical Research - Site Number:8400021, Peoria
- One of a Kind Clinical Research Center AZ, LLC-Site Number: 8400061, Scottsdale
- Scottsdale Clinical Trials-Site Number: 8400145, Scottsdale
- ak 1 plis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Phoenix Children's Hospital /ID# 255766, Phoenix
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Sep 23, 2026 · NCT05995353A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance Sun City, Sun City
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Mayo Clinic Arizona, Scottsdale
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT05230173A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Phoenix Children's Hospital, Phoenix
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 3, 2026 · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Phoenix Children's Hospital, Phoenix
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital - Thomas Rd - PIN, Phoenix
Ap rekriteFaz 3
Laj 2 ak plis · Tout sèks · Mizajou May 7, 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Scottsdale Gastroenterology Specialists, Scottsdale
- GI Alliance -Gurnee, Sun City
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 27, 2026 · NCT06456593A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400024, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Mar 27, 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Scottsdale
- Mirador Therapeutics Selected Site, Sun City
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Mayo Clinic Arizona, Scottsdale
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Dec 10, 2025 · NCT06721962Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.